Literature DB >> 35693048

Rhino-orbito-cerebral mucormycosis in an acute lymphoblastic leukemia pediatric patient. Case report and review of literature.

Cindy Carolina Abril Rincón1, Carlos Ramiro Silva-Ramos2, Joel Amuruz Arancibia3, Ma Camila Prada-Avella4,5, Amaranto Suárez4,5.   

Abstract

Mucormycosis is a disease caused by opportunistic fungi of the order Mucorales that generally affects immunocompromised patients or those with underlying disease. It has a high mortality rate and is the third most common invasive fungal infection. The following is a case report of a 12-year-old pediatric patient diagnosed with B-cell acute lymphoblastic leukemia, who presented an aggressive infectious disease two months after beginning chemotherapy, which began in the right frontal and maxillary sinuses, with subsequent progression and extension, progressively deteriorating the patient's clinical status. Culture and biopsy of the affected areas were performed, confirming by histopathology and isolation a rhino-orbito-cerebral mucormycosis due to Actinomucor elegans. The patient was treated with specific antifungal therapy as an inpatient and left the service after obtaining negative cultures, continuing with outpatient antifungal treatment.
Copyright © 2016 - 2022 InfezMed.

Entities:  

Keywords:  amphotericin B; leukemia; mucormycosis; pediatrics; posaconazole

Year:  2022        PMID: 35693048      PMCID: PMC9177182          DOI: 10.53854/liim-3002-17

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  20 in total

Review 1.  Mucormycosis treatment: Recommendations, latest advances, and perspectives.

Authors:  K Brunet; B Rammaert
Journal:  J Mycol Med       Date:  2020-06-20       Impact factor: 2.391

2.  [Successful treatment of a persistent rhino-cerebral mucormycosis in a pediatric patient with a debut of acute lymphoblastic leukemia].

Authors:  Fernanda Cofré; Milena Villarroel; Loreto Castellón; María E Santolaya
Journal:  Rev Chilena Infectol       Date:  2015-08       Impact factor: 0.520

3.  The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.

Authors:  Livio Pagano; Morena Caira; Anna Candoni; Massimo Offidani; Luana Fianchi; Bruno Martino; Domenico Pastore; Marco Picardi; Alessandro Bonini; Anna Chierichini; Rosa Fanci; Cecilia Caramatti; Rosangela Invernizzi; Daniele Mattei; Maria Enza Mitra; Lorella Melillo; Franco Aversa; Maria Teresa Van Lint; Paolo Falcucci; Caterina Giovanna Valentini; Corrado Girmenia; Annamaria Nosari
Journal:  Haematologica       Date:  2006-08       Impact factor: 9.941

4.  Successful Treatment of Rhino-Orbital-Cerebral Mucormycosis in a Child With Leukemia.

Authors:  Thorbjørn S R Jensen; Maiken C Arendrup; Christian von Buchvald; Thomas L Frandsen; Marianne Juhler; Ulrikka Nygaard
Journal:  J Pediatr Hematol Oncol       Date:  2017-05       Impact factor: 1.289

5.  Treating childhood acute lymphoblastic leukemia without cranial irradiation.

Authors:  Ching-Hon Pui; Dario Campana; Deqing Pei; W Paul Bowman; John T Sandlund; Sue C Kaste; Raul C Ribeiro; Jeffrey E Rubnitz; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; Larry E Kun; Sima Jeha; Cheng Cheng; Scott C Howard; Vickey Simmons; Amy Bayles; Monika L Metzger; James M Boyett; Wing Leung; Rupert Handgretinger; James R Downing; William E Evans; Mary V Relling
Journal:  N Engl J Med       Date:  2009-06-25       Impact factor: 91.245

6.  ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.

Authors:  Frederic Tissot; Samir Agrawal; Livio Pagano; Georgios Petrikkos; Andreas H Groll; Anna Skiada; Cornelia Lass-Flörl; Thierry Calandra; Claudio Viscoli; Raoul Herbrecht
Journal:  Haematologica       Date:  2016-12-23       Impact factor: 9.941

7.  Invasive mucormycosis during treatment for acute lymphoblastic leukaemia-successful management of two life-threatening diseases.

Authors:  Andreas Trobisch; R Marterer; G Gorkiewicz; S Flaschberger; H Lackner; M Seidel; D Sperl; A Karastaneva; B Kohlmaier; M Egger; C Urban; M Benesch; V Strenger
Journal:  Support Care Cancer       Date:  2019-08-14       Impact factor: 3.603

8.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.

Authors:  O A Cornely; S Arikan-Akdagli; E Dannaoui; A H Groll; K Lagrou; A Chakrabarti; F Lanternier; L Pagano; A Skiada; M Akova; M C Arendrup; T Boekhout; A Chowdhary; M Cuenca-Estrella; T Freiberger; J Guinea; J Guarro; S de Hoog; W Hope; E Johnson; S Kathuria; M Lackner; C Lass-Flörl; O Lortholary; J F Meis; J Meletiadis; P Muñoz; M Richardson; E Roilides; A M Tortorano; A J Ullmann; A van Diepeningen; P Verweij; G Petrikkos
Journal:  Clin Microbiol Infect       Date:  2014-04       Impact factor: 8.067

Review 9.  Overview of therapeutic drug monitoring.

Authors:  Ju Seop Kang; Min Ho Lee
Journal:  Korean J Intern Med       Date:  2009-03       Impact factor: 3.165

10.  Recurrent Rhino-Ocular-Cerebral Mucormycosis in a Leukemic Child: A Case Report and Review of Pediatric Literature.

Authors:  Francesco De Leonardis; Teresa Perillo; Giuseppe Giudice; Gianfranco Favia; Nicola Santoro
Journal:  Pediatr Rep       Date:  2015-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.